RNA sequencing identifies differences in immune profiles of tumors from pediatric neuroblastoma patients with Opsoclonus myoclonus syndrome

RNA sequencing for insights into immuno-oncology research

Opsoclonus myoclonus syndrome (OMS) is a rare, paraneoplastic neurological disorder that presents in 2-3% of pediatric neuroblastoma (NBL) cases.

NBL patients presenting with OMS have a 70-80% survival rate. OMS-associated neuroblastomas have demonstrated increase lymphocyte infiltration, but little is known about the molecular basis of this disorder.

Download our poster, presented at the 2018 EORTC-NCI-AACR, which highlights our goal to utilize RNA sequencing in order to better understand the genomic difference between NBL tumors from patients with and without OMS.

Complete the form below to access this scientific poster